|Bid||168.40 x 800|
|Ask||171.51 x 900|
|Day's Range||168.15 - 170.40|
|52 Week Range||166.30 - 210.19|
|Beta (3Y Monthly)||0.90|
|PE Ratio (TTM)||13.43|
|Earnings Date||Jul 24, 2019 - Jul 29, 2019|
|Forward Dividend & Yield||5.80 (3.23%)|
|1y Target Est||206.10|
Medicines Company announced interim results Saturday from the ongoing Phase 2 ORION-3 study that is evaluating the efficacy, safety and tolerability of inclisiran 300 mg in patients with atherosclerotic cardiovascular disease and elevated LDL cholesterol. The results show a consistent lowering of LDL cholesterol by more than 50 percent, with an overall follow-up of up to three years. The results were presented as a late-breaking presentation at the National Lipid Association Scientific Sessions in Miami.
Ligand (LGND) grants exclusive worldwide rights to a pre-clinical cancer candidate discovered using Vernalis Design platform to Cumulus Oncology.
Biotech companies Iovance Biotherapeutics, MacroGenics and Mirati Therapeutics were among the winners in a slew of data for cancer treatments released late Wednesday. Stocks rose Thursday.
THOUSAND OAKS, Calif., May 16, 2019 /PRNewswire/ -- Amgen (AMGN) will present at the RBC Health Care Conference at 8:30 a.m. ET and at the UBS Global Healthcare Conference at 2 p.m. ET on Tuesday, May 21, 2019, in New York City. Elliott M. Levy, M.D., senior vice president of Global Development at Amgen, will present at both conferences. Live audio of the presentation can be accessed from the Events Calendar on Amgen's website, www.amgen.com, under Investors.
Mirati Therapeutics, Inc. (NASDAQ: MRTX ) shares were rallying by about 15 percent Thursday as traders circulated word that drugmaker Amgen, Inc. (NASDAQ: AMGN ) KRAS G12C inhibitor abstract showed promising ...
The drug development pipelines of Gilead Sciences, Amgen and Biogen are running thin, and the companies might need to M&A to get going again, according to JPMorgan.
THOUSAND OAKS, Calif., May 15, 2019 /PRNewswire/ -- Amgen (AMGN) today announced that data from its oncology pipeline will be presented at the 55th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, May 31-June 4, 2019. Seven investigational assets will be featured across a range of hematologic malignancies and solid tumors. "Biology and human genetics have been the foundation of Amgen's innovation for the last four decades," said David M. Reese, M.D., executive vice president of Research and Development at Amgen.
With rapid growth projected for the market for wearable drug delivery devices, investors would be wise to consider some of the key players in the business. Two standouts are Boston-area-based Insulet (PODD) and West Pharmaceutical Services (WST), which is headquartered in Exton, Pennsylvania. Warning! GuruFocus has detected 4 Warning Signs with PODD.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on May 14) Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ) Avedro Inc ...
AbbVie (ABBV) resolves its litigation with Boehringer Ingelheim over U.S. patents for its blockbuster rheumatoid arthritis drug, Humira.
Lilly's (LLY) Cyramza gets FDA approval to treat AFP-high hepatocellular carcinoma (HCC), a common form of liver cancer. FDA removes boxed warning from label.
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift...
Biotech stocks saw a reversal in sentiment as the week saw an earnings deluge from small-, micro- and nano-cap biotechs and some M&A activity . Here are some key catalysts for the unfolding week that should ...
THOUSAND OAKS, Calif. , May 10, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Bank of America Merrill Lynch 2019 Health Care Conference at 10 a.m. PT on Wednesday, May 15, 2019 . David W. ...
Eli Lilly and Co has pulled ahead in a three-way race with Amgen Inc and Teva Pharmaceutical Industries Ltd in attracting new patients to a new class of migraine drugs, and seeks to build on that advantage by stressing that its therapy can completely prevent headaches in a small percentage of patients. Weekly U.S. prescription data from IQVIA, an analytics provider to the life sciences industry, showed that Lilly’s therapy Emgality claimed the largest share of first-time patients at 37.7 percent, for the first time outstripping Amgen’s Aimovig, whose share dropped to 37.2 percent as of April 26. Teva came in at a 25.1 percent share, according to an analyst who reviewed the data.
Let's take a sneak peek at some ETFs having high exposure to some impactful biotechnological companies on the release of Q1 earnings results.
Allergan's (AGN) stock declines slightly in pre-market trading despite the company delivering earnings and revenue beat in the first quarter while marginally raising its guidance
Amgen Inc NASDAQ/NGS:AMGNView full report here! Summary * Perception of the company's creditworthiness is negative * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is low * Economic output in this company's sector is expanding Bearish sentimentShort interest | PositiveShort interest is extremely low for AMGN with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting AMGN. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding AMGN totaled $1.21 billion. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | PositiveAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, and is accelerating. Credit worthinessCredit default swap | NegativeThe current level displays a negative indicator. AMGN credit default swap spreads are near their highest levels for the past 1 year, which indicates the market's more negative perception of the company's credit worthiness.Please send all inquiries related to the report to firstname.lastname@example.org.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.